Biogen (BIIB) Stock Forecast, Price Target & Predictions
BIIB Stock Forecast
Biogen stock forecast is as follows: an average price target of $291.45 (represents a 47.09% upside from BIIB’s last price of $198.15) and a rating consensus of 'Buy', based on 34 wall street analysts offering a 1-year stock forecast.
BIIB Price Target
The average price target for Biogen (BIIB) is $291.45 based on 1-year price targets from 34 Wall Street analysts in the past 3 months, with a price target range of $405.00 to $209.00. This represents a potential 47.09% upside from BIIB's last price of $198.15.
BIIB Analyst Ratings
According to 34 Wall Street analysts, Biogen's rating consensus is 'Buy'. The analyst rating breakdown for BIIB stock is 0 'Strong Buy' (0.00%), 27 'Buy' (79.41%), 7 'Hold' (20.59%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Biogen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 29, 2024 | Brian Skorney | Robert W. Baird | $294.00 | $212.70 | 38.22% | 48.37% |
| Jul 26, 2024 | Salveen Richter | Goldman Sachs | $342.00 | $211.17 | 61.95% | 72.60% |
| Jul 26, 2024 | Christopher Raymond | Piper Sandler | $307.00 | $211.17 | 45.38% | 54.93% |
| Jul 26, 2024 | Brian Abrahams | RBC Capital | $282.00 | $214.16 | 31.68% | 42.32% |
| Jul 12, 2024 | Christopher Raymond | Piper Sandler | $313.00 | $236.80 | 32.18% | 57.96% |
| Jul 11, 2024 | Terence Flynn | Morgan Stanley | $311.00 | $232.75 | 33.62% | 56.95% |
| Jun 12, 2024 | George Farmer | Scotiabank | $275.00 | $230.28 | 19.42% | 38.78% |
| May 23, 2024 | Evan David Seigerman | BMO Capital | $260.00 | $220.00 | 18.18% | 31.21% |
| May 22, 2024 | Paul Matteis | Stifel Nicolaus | $275.00 | $225.21 | 22.11% | 38.78% |
| May 22, 2024 | Christopher Raymond | Raymond James | $335.00 | $225.21 | 48.75% | 69.06% |
The latest Biogen stock forecast, released on Jul 29, 2024 by Brian Skorney from Robert W. Baird, set a price target of $294.00, which represents a 38.22% increase from the stock price at the time of the forecast ($212.70), and a 48.37% increase from BIIB last price ($198.15).
Biogen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 6 | 16 |
| Avg Price Target | - | $308.17 | $290.13 |
| Last Closing Price | $198.15 | $198.15 | $198.15 |
| Upside/Downside | -100.00% | 55.52% | 46.42% |
In the current month, the average price target of Biogen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Biogen's last price of $198.15. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 05, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 19, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 26, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jul 26, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 11, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 03, 2024 | William Blair | Outperform | Outperform | Hold |
| Jun 26, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 26, 2024 | Wedbush | Buy | Buy | Hold |
| Jun 12, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
Biogen's last stock rating was published by BMO Capital on Sep 05, 2024. The company gave BIIB a "Outperform" rating, the same as its previous rate.
Biogen Financial Forecast
Biogen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.53B | $2.46B | $2.46B | $2.54B | $2.51B | $2.59B | $2.53B | $2.73B | $2.78B | $2.77B | $2.69B | $2.85B | $3.38B | $3.68B | $3.53B | $3.67B | $3.60B |
| Avg Forecast | $2.51B | $2.47B | $2.41B | $2.33B | $2.39B | $2.37B | $2.42B | $2.38B | $2.45B | $2.43B | $2.39B | $2.31B | $2.47B | $2.40B | $2.37B | $2.34B | $2.45B | $2.47B | $2.47B | $2.50B | $2.62B | $2.67B | $2.61B | $2.65B | $2.80B | $3.33B | $3.43B | $3.42B | $3.54B | $3.54B |
| High Forecast | $2.65B | $2.61B | $2.55B | $2.47B | $2.52B | $2.50B | $2.55B | $2.51B | $2.58B | $2.56B | $2.53B | $2.44B | $2.56B | $2.51B | $2.50B | $2.47B | $2.58B | $2.61B | $2.62B | $2.65B | $2.77B | $2.83B | $2.76B | $2.81B | $2.96B | $3.53B | $3.63B | $3.62B | $3.75B | $3.75B |
| Low Forecast | $2.44B | $2.40B | $2.34B | $2.26B | $2.32B | $2.29B | $2.35B | $2.30B | $2.37B | $2.35B | $2.32B | $2.24B | $2.35B | $2.29B | $2.29B | $2.27B | $2.37B | $2.39B | $2.35B | $2.37B | $2.49B | $2.53B | $2.48B | $2.52B | $2.66B | $3.17B | $3.26B | $3.25B | $3.36B | $3.36B |
| # Analysts | 21 | 11 | 15 | 11 | 10 | 16 | 10 | 10 | 19 | 22 | 13 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.04% | 1.05% | 1.04% | 1.02% | 1.05% | 1.01% | 1.04% | 1.04% | 1.06% | 1.02% | 1.02% | 1.01% | 1.07% | 1.03% | 1.04% | 1.02% |
Biogen's average Quarter revenue forecast for Dec 23 based on 27 analysts is $2.47B, with a low forecast of $2.35B, and a high forecast of $2.56B. BIIB's average Quarter revenue forecast represents a -2.54% decrease compared to the company's last Quarter revenue of $2.53B (Sep 23).
Biogen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 21 | 11 | 15 | 11 | 10 | 16 | 10 | 10 | 19 | 22 | 13 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $371.70M | $708.60M | $577.10M | $515.10M | $971.00M | $1.04B | $739.60M | $1.01B | $502.80M | $168.70M | $666.00M | $517.60M | $1.13B | $2.17B | $1.86B | $1.87B | $2.13B |
| Avg Forecast | $875.11M | $860.70M | $839.72M | $813.37M | $832.25M | $824.39M | $842.55M | $827.80M | $852.59M | $847.20M | $833.39M | $906.78M | $859.02M | $835.92M | $824.48M | $824.35M | $851.76M | $461.13M | $861.72M | $749.41M | $912.66M | $929.83M | $908.92M | $626.36M | $974.21M | $1.16B | $1.19B | $1.52B | $1.23B | $1.23B |
| High Forecast | $924.26M | $909.04M | $886.88M | $859.05M | $878.99M | $870.69M | $889.86M | $874.29M | $900.47M | $892.33M | $880.20M | $1.09B | $890.44M | $875.55M | $870.78M | $989.22M | $899.60M | $553.35M | $912.54M | $899.29M | $966.48M | $984.67M | $962.52M | $751.63M | $1.03B | $1.23B | $1.27B | $1.82B | $1.31B | $1.31B |
| Low Forecast | $848.47M | $834.50M | $814.16M | $788.61M | $806.91M | $799.30M | $816.90M | $802.59M | $826.63M | $819.42M | $808.02M | $725.43M | $817.11M | $796.46M | $799.38M | $659.48M | $825.83M | $368.90M | $818.31M | $599.53M | $866.69M | $882.99M | $863.13M | $501.09M | $925.14M | $1.10B | $1.13B | $1.21B | $1.17B | $1.17B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.44% | 0.86% | 0.70% | 0.60% | 2.11% | 1.21% | 0.99% | 1.11% | 0.54% | 0.19% | 1.06% | 0.53% | 0.98% | 1.81% | 1.22% | 1.52% | 1.73% |
27 analysts predict BIIB's average Quarter EBITDA for Dec 23 to be $859.02M, with a high of $890.44M and a low of $817.11M. This is 131.10% upper than Biogen's previous annual EBITDA (Sep 23) of $371.70M.
Biogen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 21 | 11 | 15 | 11 | 10 | 16 | 10 | 10 | 19 | 22 | 13 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-68.10M | $591.60M | $387.90M | $550.40M | $1.13B | $1.06B | $221.80M | $-38.20M | $329.20M | $448.50M | $410.20M | $357.90M | $701.50M | $1.54B | $1.40B | $1.44B | $1.55B |
| Avg Forecast | $653.85M | $517.97M | $544.60M | $508.36M | $573.79M | $549.44M | $623.89M | $606.78M | $497.28M | $550.00M | $593.52M | $431.38M | $464.54M | $579.74M | $551.00M | $392.17M | $509.06M | $301.91M | $592.38M | $356.51M | $492.71M | $596.18M | $663.72M | $385.78M | $699.11M | $1.18B | $1.17B | $1.14B | $1.17B | $1.21B |
| High Forecast | $701.59M | $555.79M | $584.36M | $545.47M | $615.68M | $589.56M | $669.44M | $651.08M | $533.58M | $642.39M | $636.85M | $517.66M | $567.45M | $653.84M | $591.22M | $470.60M | $546.23M | $362.30M | $637.80M | $427.82M | $530.48M | $641.88M | $714.60M | $462.94M | $752.70M | $1.27B | $1.26B | $1.37B | $1.26B | $1.30B |
| Low Forecast | $627.97M | $497.47M | $523.05M | $488.24M | $551.08M | $527.70M | $599.20M | $582.77M | $477.60M | $496.59M | $570.03M | $345.11M | $404.27M | $451.88M | $529.19M | $313.73M | $488.92M | $241.53M | $553.59M | $285.21M | $460.44M | $557.13M | $620.25M | $308.63M | $653.33M | $1.10B | $1.09B | $915.12M | $1.09B | $1.13B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.12% | 1.07% | 0.99% | 1.08% | 3.76% | 1.79% | 0.62% | -0.08% | 0.55% | 0.68% | 1.06% | 0.51% | 0.59% | 1.32% | 1.22% | 1.23% | 1.28% |
Biogen's average Quarter net income forecast for Sep 23 is $579.74M, with a range of $451.88M to $653.84M. BIIB's average Quarter net income forecast represents a -2.01% decrease compared to the company's last Quarter net income of $591.60M (Jun 23).
Biogen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 21 | 11 | 15 | 11 | 10 | 16 | 10 | 10 | 19 | 22 | 13 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $788.20M | $548.00M | $605.00M | $632.80M | $563.30M | $572.60M | $634.90M | $787.90M | $654.10M | $637.30M | $595.00M | $806.20M | $573.10M | $555.10M | $570.10M | $664.90M | $554.50M |
| Avg Forecast | $547.89M | $538.87M | $525.73M | $509.23M | $521.05M | $516.14M | $527.50M | $518.27M | $533.79M | $530.41M | $521.77M | $901.53M | $537.81M | $523.35M | $516.19M | $819.57M | $533.27M | $599.88M | $539.51M | $745.07M | $571.40M | $582.15M | $569.06M | $559.58M | $609.94M | $727.27M | $748.03M | $466.11M | $771.61M | $771.73M |
| High Forecast | $578.66M | $569.13M | $555.26M | $537.83M | $550.32M | $545.12M | $557.13M | $547.37M | $563.77M | $558.67M | $551.07M | $1.08B | $557.49M | $548.16M | $545.18M | $983.49M | $563.22M | $719.86M | $571.32M | $894.08M | $605.09M | $616.48M | $602.61M | $671.50M | $645.90M | $770.15M | $792.14M | $559.33M | $817.12M | $817.24M |
| Low Forecast | $531.21M | $522.46M | $509.73M | $493.73M | $505.19M | $500.42M | $511.44M | $502.49M | $517.54M | $513.02M | $505.88M | $721.22M | $511.58M | $498.64M | $500.47M | $655.66M | $517.04M | $479.91M | $512.33M | $596.05M | $542.61M | $552.82M | $540.39M | $447.67M | $579.21M | $690.63M | $710.35M | $372.89M | $732.74M | $732.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51% | 1.06% | 0.74% | 1.19% | 0.94% | 1.06% | 0.85% | 1.38% | 1.12% | 1.12% | 1.06% | 1.32% | 0.79% | 0.74% | 1.22% | 0.86% | 0.72% |
Biogen's average Quarter SG&A projection for Dec 23 is $537.81M, based on 27 Wall Street analysts, with a range of $511.58M to $557.49M. The forecast indicates a -31.77% fall compared to BIIB last annual SG&A of $788.20M (Sep 23).
Biogen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 21 | 11 | 15 | 11 | 10 | 16 | 10 | 10 | 19 | 22 | 13 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.47 | $4.09 | $2.69 | $3.82 | $7.86 | $7.25 | $1.51 | $-0.26 | $2.22 | $3.00 | $2.70 | $2.33 | $4.47 | $9.60 | $8.10 | $8.10 | $8.40 |
| Avg Forecast | $4.48 | $3.55 | $3.73 | $3.48 | $3.93 | $3.77 | $4.28 | $4.16 | $3.41 | $3.77 | $4.07 | $3.47 | $3.18 | $3.97 | $3.78 | $3.28 | $3.49 | $4.13 | $4.06 | $4.34 | $3.38 | $4.09 | $4.55 | $4.98 | $4.79 | $8.09 | $8.02 | $7.72 | $8.03 | $8.30 |
| High Forecast | $4.81 | $3.81 | $4.01 | $3.74 | $4.22 | $4.04 | $4.59 | $4.46 | $3.66 | $4.40 | $4.36 | $3.72 | $3.89 | $4.48 | $4.05 | $3.52 | $3.74 | $4.43 | $4.37 | $4.67 | $3.64 | $4.40 | $4.90 | $5.36 | $5.16 | $8.71 | $8.64 | $8.32 | $8.64 | $8.94 |
| Low Forecast | $4.30 | $3.41 | $3.58 | $3.35 | $3.78 | $3.62 | $4.11 | $3.99 | $3.27 | $3.40 | $3.91 | $3.33 | $2.77 | $3.10 | $3.63 | $3.15 | $3.35 | $3.96 | $3.79 | $4.06 | $3.16 | $3.82 | $4.25 | $4.66 | $4.48 | $7.56 | $7.50 | $7.22 | $7.50 | $7.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.12% | 1.08% | 0.82% | 1.09% | 1.91% | 1.79% | 0.35% | -0.08% | 0.54% | 0.66% | 0.54% | 0.49% | 0.55% | 1.20% | 1.05% | 1.01% | 1.01% |
According to 26 Wall Street analysts, Biogen's projected average Quarter EPS for Sep 23 is $3.97, with a low estimate of $3.10 and a high estimate of $4.48. This represents a -2.85% decrease compared to BIIB previous annual EPS of $4.09 (Jun 23).
Biogen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $29.83 | $46.29 | 55.18% | Hold |
| BIIB | Biogen | $198.21 | $291.45 | 47.04% | Buy |
| GSK | GSK | $42.56 | $58.00 | 36.28% | Hold |
| BMY | Bristol-Myers Squibb Company | $49.49 | $65.43 | 32.21% | Hold |
| MRK | Merck | $118.29 | $127.74 | 7.99% | Buy |
| JNJ | Johnson & Johnson | $167.07 | $176.29 | 5.52% | Buy |
| SNY | Sanofi | $56.91 | $57.36 | 0.79% | Buy |
| NVS | Novartis | $115.70 | $115.67 | -0.03% | Hold |
| GILD | Gilead Sciences | $83.05 | $80.00 | -3.67% | Buy |
| ABBV | AbbVie | $193.45 | $167.54 | -13.39% | Buy |
| AMGN | Amgen | $332.80 | $286.95 | -13.78% | Buy |
BIIB Forecast FAQ
Is Biogen a good buy?
Yes, according to 34 Wall Street analysts, Biogen (BIIB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 27 'Buy' recommendations, accounting for 79.41% of BIIB's total ratings.
What is BIIB's price target?
Biogen (BIIB) average price target is $291.45 with a range of $209 to $405, implying a 47.09% from its last price of $198.15. The data is based on 34 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Biogen stock go up soon?
According to Wall Street analysts' prediction for BIIB stock, the company can go up by 47.09% (from the last price of $198.15 to the average price target of $291.45), up by 104.39% based on the highest stock price target, and up by 5.48% based on the lowest stock price target.
Can Biogen stock reach $300?
BIIB's highest twelve months analyst stock price target of $405 supports the claim that Biogen can reach $300 in the near future.
What are Biogen's analysts' financial forecasts?
Biogen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.55B (high $10.09B, low $9.26B), average EBITDA is $3.33B (high $3.51B, low $3.23B), average net income is $2.35B (high $2.53B, low $2.26B), average SG&A $2.08B (high $2.2B, low $2.02B), and average EPS is $16.13 (high $17.31, low $15.5). BIIB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $9.73B (high $10.27B, low $9.43B), average EBITDA is $3.39B (high $3.58B, low $3.29B), average net income is $2.22B (high $2.39B, low $2.14B), average SG&A $2.12B (high $2.24B, low $2.06B), and average EPS is $15.25 (high $16.36, low $14.65).
Did the BIIB's actual financial results beat the analysts' financial forecasts?
Based on Biogen's last annual report (Dec 2022), the company's revenue was $10.17B, beating the average analysts forecast of $9.89B by 2.89%. Apple's EBITDA was $2.69B, missing the average prediction of $2.92B by -8.14%. The company's net income was $3.05B, beating the average estimation of $1.76B by 73.13%. Apple's SG&A was $2.4B, missing the average forecast of $2.42B by -0.58%. Lastly, the company's EPS was $20.96, beating the average prediction of $16.02 by 30.88%. In terms of the last quarterly report (Sep 2023), Biogen's revenue was $2.53B, beating the average analysts' forecast of $2.4B by 5.44%. The company's EBITDA was $371.7M, missing the average prediction of $835.92M by -55.53%. Biogen's net income was $-68.1M, missing the average estimation of $579.74M by -111.75%. The company's SG&A was $788.2M, beating the average forecast of $523.35M by 50.61%. Lastly, the company's EPS was $-0.47, missing the average prediction of $3.97 by -111.83%